Summarized by Masters of Longevity from PR Newswire.
The C‑MIC IV trial started and enrolled its first patient under double‑blind sham control.

Key Takeaways
- Sixty patients will be randomized to active or sham treatment.
- Participants have symptomatic reduced‑EF heart failure above 20%.
- The trial is randomized double‑blind and sham‑controlled.



